Thus, the patients in our study whose treatment was suspended or permanently interrupted and who received an average of 11 cycles of trastuzumab may have experienced some benefit in disease control based on the FinHER study,(18) but this benefit may be lower than would be expected with complete treatment based on the PHARE study.(19) Another meta-analysis showed that, compared with short-term treatment, one year of trastuzumab prolonged OS and DFS in patients with HER2-positive early-stage breast cancer and that one year should be used as the standard of treatment.(20). This evidence concerns the gene ERBB2 and breast carcinoma.